Immunostimulatory and antigen delivery properties of liposomes made up of total polar lipids from non-pathogenic bacteria leads to efficient induction of both innate and adaptive immune responses

Vaccine

Volumn 29, Issue 13, 2011, Pages 2381-2391

  Faisal, Syed M ^a   Chen, Jenn wei ^a   McDonough, Sean P ^a   Chang, Chao Fu ^b   Teng, Ching Hao ^c   Chang, Yung Fu ^a  

^a Department of Obstetrics Gynecology   (United States)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Adjuvant; Antigen delivery vehicle; Immunostimulatory lipids; L. biflexa; Liposome; M. Smegmatis; Total polar lipids

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; LEPTOSOME; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SMEGMOSOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; LEPTOSPIRA; LEPTOSPIRA BIFLEXA; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MEMBRANE FUSION; MOUSE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; ANTIGENS, SURFACE; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DRUG CARRIERS; FEMALE; LEPTOSPIRA; LIPOSOMES; MACROPHAGES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM SMEGMATIS; OVALBUMIN; PHOSPHOLIPIDS; T-LYMPHOCYTES;

EID: 79952363514     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.110     Document Type: Article

References (77)

1. Burnette W.N. Recombinant subunit vaccines. Curr Opin Biotechnol 1991, 2(6):882-892.
2. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008, 364(2):272-280.
3. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(3):155-172.
4. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11(3):293-306.
5. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6(5):685-698.
6. Relyveld E.H., Bizzini B., Gupta R.K. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998, 16(9-10):1016-1023.
7. Hunter R.L. Overview of vaccine adjuvants: present and future. Vaccine 2002, 20(Suppl. 3):S7-12.
8. Alving C.R. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim Biophys Acta 1992, 1113(3-4):307-322.
9. Faisal S.M., Yan W., McDonough S.P., Chang Y.F. Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity. Vaccine 2009, 27(3):378-387.
10. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 1992, 89(1):358-362.
11. Gregoriadis G. The immunological adjuvant and vaccine carrier properties of liposomes. J Drug Target 1994, 2(5):351-356.
12. Kirby D.J., Rosenkrands I., Agger E.M., Andersen P., Coombes A.G., Perrie Y. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J Drug Target 2008, 16(7):543-554.
13. Stewart V.A., McGrath S.M., Walsh D.S., Davis S., Hess A.S., Ware L.A., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 2006, 24(42-43):6483-6492.
14. Sanchez Y., Ionescu-Matiu I., Dreesman G.R., Kramp W., Six H.R., Hollinger F.B., et al. Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant alum, and liposomes. Infect Immun 1980, 30(3):728-733.
15. Ambrosch F., Wiedermann G., Jonas S., Althaus B., Finkel B., Gluck R., et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997, 15(11):1209-1213.
16. Vandepapeliere P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26(10):1375-1386.
17. Harokopakis E., Hajishengallis G., Michalek S.M. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect Immun 1998, 66(9):4299-4304.
18. Lachman L.B., Ozpolat B., Rao X.M. Cytokine-containing liposomes as vaccine adjuvants. Eur Cytokine Netw 1996, 7(4):693-698.
19. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., Alving C.R. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect Immun 1998, 66(6):2859-2865.
20. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
21. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91(3):295-298.
22. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54(6):777-785.
23. Phillips N.C., Emili A. Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production. Vaccine 1992, 10(3):151-158.
24. Therien H.M., Shahum E., Fortin A. Liposome adjuvanticity: influence of dose and protein:lipid ratio on the humoral response to encapsulated and surface-linked antigen. Cell Immunol 1991, 136(2):402-413.
25. Kawai T., Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007, 13(11):460-469.
26. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl.):S63-S68.
27. Martin M., Michalek S.M., Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003, 71(5):2498-2507.
28. Yoo Y.C., Yoshimatsu K., Koike Y., Hatsuse R., Yamanishi K., Tanishita O., et al. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine. Vaccine 1998, 16(2-3):216-224.
29. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005, 1718(1-2):22-31.
30. Muller M.R., Wiesmuller K.H., Jung G., Loop T., Humar M., Pfannes S.D., et al. Lipopeptide adjuvants: monitoring and comparison of P3CSK4- and LPS-induced gene transcription. Int Immunopharmacol 2002, 2(8):1065-1077.
31. Ahmad N., Deeba F., Faisal S.M., Khan A., Agrewala J.N., Dwivedi V., et al. Role of fusogenic non-PC liposomes in elicitation of protective immune response against experimental murine salmonellosis. Biochimie 2006, 88(10):1391-1400.
32. Holten-Andersen L., Doherty T.M., Korsholm K.S., Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004, 72(3):1608-1617.
33. Krishnan L., Dicaire C.J., Patel G.B., Sprott G.D. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 2000, 68(1):54-63.
34. Rosenkrands I., Agger E.M., Olsen A.W., Korsholm K.S., Andersen C.S., Jensen K.T., et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 2005, 73(9):5817-5826.
35. Sharma S.K., Dube A., Nadeem A., Khan S., Saleem I., Garg R., et al. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine 2006, 24(11):1800-1810.
36. Faisal S.M., Yan W., McDonough S.P., Chang C.F., Pan M.J., Chang Y.F. Leptosome-entrapped leptospiral antigens conferred significant higher levels of protection than those entrapped with PC-liposomes in a hamster model. Vaccine 2009, 27(47):6537-6545.
37. Syed F.M., Khan M.A., Nasti T.H., Ahmad N., Mohammad O. Antigen entrapped in the escheriosomes leads to the generation of CD4(+) helper and CD8(+) cytotoxic T cell response. Vaccine 2003, 21(19-20):2383-2393.
38. Faisal S.M., Yan W., McDonough S.P., Mohammed H.O., Divers T.J., Chang Y.F. Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis. Vaccine 2009, 27(44):6129-6136.
39. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37(8):911-917.
40. Brandl M., Gregoriadis G. Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour. Biochim Biophys Acta 1994, 1196(1):65-75.
41. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176(6):1693-1702.
42. Ahmad N., Masood A.K., Owais M. Fusogenic potential of prokaryotic membrane lipids. Implication in vaccine development. Eur J Biochem 2001, 268(22):5667-5675.
43. van de Loosdrecht A.A., Beelen R.H., Ossenkoppele G.J., Broekhoven M.G., Langenhuijsen M.M. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 1994, 174(1-2):311-320.
44. Haruna H., Inaba M., Inaba K., Taketani S., Sugiura K., Fukuba Y., et al. Abnormalities of B cells and dendritic cells in SAMP1 mice. Eur J Immunol 1995, 25(5):1319-1325.
45. Faisal S.M., Yan W., Chen C.S., Palaniappan R.U., McDonough S.P., Chang Y.F. Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters. Vaccine 2008, 26(2):277-287.
46. Korzeniewski C., Callewaert D.M. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983, 64(3):313-320.
47. Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65(1-2):109-121.
48. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103(29):10834-10839.
49. Yan W., Faisal S.M., McDonough S.P., Divers T.J., Barr S.C., Chang C.F., et al. Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model. Microbes Infect 2009, 11(2):230-237.
50. Freund J. The mode of action of immunologic adjuvants. Bibl Tuberc 1956, 10(10):130-148.
51. Koike Y., Yoo Y.C., Mitobe M., Oka T., Okuma K., Tono-oka S., et al. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Vaccine 1998, 16(20):1982-1989.
52. Foged C., Arigita C., Sundblad A., Jiskoot W., Storm G., Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004, 22(15-16):1903-1913.
53. Krishnan L., Sad S., Patel G.B., Sprott G.D. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J Immunol 2001, 166(3):1885-1893.
54. Phillips N.C., Gagne L., Ivanoff N., Riveau G. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 1996, 14(9):898-904.
55. Sprott G.D., Dicaire C.J., Gurnani K., Sad S., Krishnan L. Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette-Guerin and adjuvant activity in vivo. Infect Immun 2004, 72(9):5235-5246.
56. Thiele L., Rothen-Rutishauser B., Jilek S., Wunderli-Allenspach H., Merkle H.P., Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. J Control Release 2001, 76(1-2):59-71.
57. Nakanishi T., Hayashi A., Kunisawa J., Tsutsumi Y., Tanaka K., Yashiro-Ohtani Y., et al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 2000, 30(6):1740-1747.
58. Barratt G., Tenu J.P., Yapo A., Petit J.F. Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta 1986, 862(1):153-164.
59. Campos M.A., Almeida I.C., Takeuchi O., Akira S., Valente E.P., Procopio D.O., et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 2001, 167(1):416-423.
60. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
61. Trinchieri G., Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol 1995, 146(7-8):423-431.
62. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80(5):707-718.
63. Lanier L.L., O'Fallon S., Somoza C., Phillips J.H., Linsley P.S., Okumura K., et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995, 154(1):97-105.
64. Audibert F.M., Lise L.D., Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993, 14(6):281-284.
65. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285(5428):732-736.
66. Wetzler L.M., Ho Y., Reiser H. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. J Exp Med 1996, 183(3):1151-1159.
67. Tough D.F., Sun S., Sprent J. T cell stimulation in vivo by lipopolysaccharide (LPS). J Exp Med 1997, 185(12):2089-2094.
68. Vogel S.N., Hilfiker M.L., Caulfield M.J. Endotoxin-induced T lymphocyte proliferation. J Immunol 1983, 130(4):1774-1779.
69. Yamamoto M., Kiyono H., Yamamoto S., Batanero E., Kweon M.N., Otake S., et al. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J Immunol 1999, 162(12):7015-7021.
70. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 1996, 272(5258):50-53.
71. Snapper C.M., Peschel C., Paul W.E. IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol 1988, 140(7):2121-2127.
72. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236(4804):944-947.
73. Markine-Goriaynoff D., van der Logt J.T., Truyens C., Nguyen T.D., Heessen F.W., Bigaignon G., et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000, 12(2):223-230.
74. Atif S.M., Salam N., Ahmad N., Hasan I.M., Jamal H.S., Sudhanshu A., et al. Sperm membrane lipid liposomes can evoke an effective immune response against encapsulated antigen in BALB/c mice. Vaccine 2008, 26(46):5874-5882.
75. Owais M., Gupta C.M. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur J Biochem 2000, 267(13):3946-3956.
76. Andersen C.S., Agger E.M., Rosenkrands I., Gomes J.M., Bhowruth V., Gibson K.J., et al. A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J Immunol 2009, 182(1):424-432.
77. Maue A.C., Eaton S.M., Lanthier P.A., Sweet K.B., Blumerman S.L., Haynes L. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J Immunol 2009, 182(10):6129-6135.